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ABSTRACT
Objectives: In cirrhotic patients, despite presence of significant metabolic abnormalities and enlarged left 
atria, we have seldom observed atrial fibrillation (AF) rhythm. The aim of this study was to evaluate the 
prevalence of AF among cirrhotic patients and comparing it with that reported in the general population. 
Materials and Methods: Medical documents of 1302 adult cirrhotic patients, booked in the waiting list of 
liver transplantation, were evaluated retrospectively. Electrocardiograms were reviewed for the presence of 
AF rhythm, and echocardiographies were reviewed to obtain left atrial (LA) size. Result: Only two patients 
(0.15%) were detected to have AF rhythm, which was significantly lower than that reported in our general 
population, even after age and sex adjustment. Six hundred and sixty-eight patients (51%) had enlarged left 
atria (LA diameter more than 39mm); both AF patients belonged to this group. Conclusion: The result of this 
study suggests the protective effect of liver cirrhosis on development of atrial fibrillation. Further studies are 
needed to verify the possible mechanisms.
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shown that increased serum levels of inflammatory 
markers such C-reactive protein (CRP) and Interleukin-6 
(IL-6) is associated with high occurrence of AF rhythm.  [2] 
On the other hand, consumption of anti-inflammatory 
medications such as statins, angiotensin converting enzyme 
(ACE) inhibitors and aldosterone receptor blockers (ARBs) 
seems to be effective to reduce the recurrence of AF.[3,4]
The size of left atrium (LA) is also an objective index to 
predict the initiation of AF. Patients with increased LA 
dimensions are predisposed to the development of either 
paroxysmal or chronic AF.[5] LA enlargement starts a chain 
of events, which causes activation of renin-angiotensin-
aldosterone system that leads to progressive atrial fibrosis 
and remodeling, which is known to play a major role in 
initiation of AF.[6]
According to our previous studies, LA size and volume 
increase in patients with liver cirrhosis.[7,8] However 
unexpectedly, during evaluation of cirrhotic patients in our 
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INTRODUCTION
An electrocardiogram (ECG) showing atrial fibrillation 
(AF) was first published in 1906[1] but the pathophysiology 
has remained to some extent undiscovered. In recent years, 
the pathophysiologic concept of AF has widely extended 
from the effect of conventional risk factors such as age, 
diabetes mellitus and hypertension to recently interesting 
factors such as inflammation and atrial remodeling. 
The severity of inflammation is proportional with the 
amount of inhomogenicity in atrial conduction, which 
can potentiate the initiation of AF. Several studies have 
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Liver Transplant Clinic, we noticed that the frequency of AF 
is substantially low. This clinical observation brought up this 
idea to our minds that liver cirrhosis may have a protective 
role against development of AF. In this study, we aimed 
to investigate the prevalence of atrial fibrillation among 
cirrhotic patients in the waiting list of liver transplant and 
to compare it with that of general population.
MATERIALS AND METHODS
Patients
A retrospective analysis of patients with proved liver 
cirrhosis, who were booked in waiting list for liver 
transplantation, was conducted in Namazee Hospital 
Transplant Centre, Shiraz, Iran. Patients with concomitant 
congenital heart disease, rheumatic heart disease and also 
those younger than 20 years old were excluded; 1302 
cirrhotic patients met the criteria to enter this study.
Electrocardiogram
A standard 12-lead resting ECG is taken for every cirrhotic 
patient in our centre as a part of routine cardiovascular 
evaluation before liver transplantation. We evaluated 1302 
ECGs available in patients’ files for the presence of AF 
rhythm; defined as absence of P wave and presence of 
fibrillatory F waves that vary in amplitude, shape and 
frequency in association with an irregular ventricular 
rhythm.
Echocardiogram
A complete transthoracic echocardiography (TTE) 
is done for every cirrhotic patient as a pat of routine 
cardiovascular evaluation before liver transplantation, and 
1261 echocardiographies were available to review. Using 
parasternal long-axis view, LA anteroposterior diameter 
was measured routinely by M-mode electrocardiography 
as the distance from the leading edge of the posterior 
aortic root to the leading edge of the posterior left 
atrial cavity at end of systole. This method is proved 
to be an accurate determinant of LA size and is also 
compatible with recommendations of “American Society 
of Echocardiography.”[9] We considered LA to be enlarged 
if the diameter was greater than 39 mm.[10]
Other comorbidities
We considered the patient as hypertensive if recorded 
systolic blood pressure was ≥140 mmHg or diastolic 
blood pressure was ≥90mmHg, or when the patient 
used antihypertensive drugs. Diabetes was defined as the 
consumption of anti-diabetic medication or a fasting blood 
sugar ≥126 mg/dL. We also checked the list of patients’ 
medications to find any drugs with a protective effect on 
AF, such as spironolactone and β-blockers.
Statistical analysis
The prevalence of AF was determined in total study 
population, for men and women, and also for different 
age groups separately. Mean LA size was calculated in total 
population also using Leven’s test, association of LA size 
with different age groups was assessed.
RESULTS
Age and sex spectrum of our study population is shown in 
Figure 1. The age group 50–59y/o with 390 participants was 
the most populated category. Only two of 1302 available 
ECGs showed AF rhythm [Table 1]. Both patients were men 
and one of them was a diabetic patient, and none of them was 
on medications such as spironolactone or β-blockers. One of 
the AF cases was a 71y/o man and the other one a 45y/o man. 
So the prevalence of AF is 0.13% among cirrhotic patients 
under 50y/o and 0.19% in the patients 50 years old or more. 
Only 2 of 1302 available ECGs showed AF rhythm. Both 
patients were men and one of them was a diabetic patient 
and none of them was on medications such as Sprinolacton 
or β-blockers. One of the AF cases was a 71y/o man and the 
other one a 45y/o man [Table 2]. So the prevalence of AF 
is 0.13% among cirrhotic patients under 50y/o and 0.19% 
in the patients 50 years old or more. Mean LA size of total 
population was 40 mm (Std. Deviation=5.54); 668 patients 
(51%) had enlarged LA (mean=44.6 mm). The maximum 
size was 60 mm belonging to a patient with normal sinus 
rhythm [Table 3]. 611 patients had ascites (47%), 162 patients 
were diabetic (12.4%) and only 35 cases were diagnosed as 
hypertensive (2.7%). Thirty percent of patients were using 
spironolactone and/or β-blocker.
Figure 1: Shows age and sex distribution of the study populationJournal of Cardiovascular Disease Research Vol. 3 / No 2 111
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DISCUSSION
A rough comparison of AF prevalence in different races 
shows that the prevalence of AF in the United States and 
European people is similar, but it seems to be lower among 
Asian people.[11]
In a cohort study in United States among nearly 3 million 
adults aged 20 years or more, the overall prevalence of 
AF was defined to be 0.95%, which changed from 0.1% 
in people younger than 55 years to 3.8% in 60 years and 
older people. It reached to 9% among those 80 years and 
older.[12] In a cross-sectional study among 65 years or older 
people in United Kingdom, prevalence of AF was found 
to be 4.7%.[13] A cross-sectional study among 40–69 years 
Korean people showed overall AF prevalence of 0.4%; in 
age group 60–69 years it reaches 1%.[14]
In Iran, the prevalence of AF is 2.8% among those 50 years 
old and more. It increases from 0.6% in patients aged 
50–59 to 1.4% in age group 60–69 and 6.4% in age group 
70–79.  [15] In our study, among 1302 cirrhotic patients, only 
two patients were found to have AF rhythm (0.15%), which 
is significantly lower than that reported in the general 
population.
LA size more than 40 mm increases the risk of development 
of AF. For example, AF occurs in more than 54% of 
patients with mitral valve stenosis and enlarged left atria.  [16] 
Among our cirrhotic patients, 668 patients had LA size 
equal to or more than 40 mm (mean=44.16 mm). Both AF 
cases belonged to this group. The prevalence of AF among 
cirrhotics with enlarged LA is surprisingly low (0.30%).
Diabetes is another risk factor for development of AF and 
is counted as an independent determinant of AF. Prevalence 
of AF in diabetics is shown to be higher than non-diabetics, 
even after adjustment for other risk factors (3.6% vs 
2.5%);[17] 12.4% of our cirrhotic patients were diabetic 
which is more than that observed in our general population 
in Iran (6.1%).[18] One of our two AF cases was diabetic, so 
prevalence of AF in cirrhotic diabetics is significantly less 
than diabetic patients without cirrhosis (0.6%).
The prevalence of AF among patients with chronic renal 
failure non on dialysis is reported to be significantly higher than 
the general population.[19] Increase in systemic inflammation 
was described as guilty by the authors. Now the question is 
that why in cirrhotic patients the scenario is different?
Low prevalence of AF despite extensive metabolic 
derangement and LA enlargement in cirrhotic patients 
may be the result of accumulation of a toxin or a humoral 
substance with possible anti-arrhythmic and/or anti-
inflammatory property, which is normally metabolized by 
a normal functioning liver.[20] Interestingly, during early 
post-transplantation period in ICU, we have noticed that 
many patients would develop AF rhythm (unpublished 
observation). The susceptibility to AF in early post-
transplantation period may be the result of detoxifying and 
metabolizing function of transplanted liver.
Lower prevalence of systemic hypertension and taking 
medications such as spironolactone and β-blockers may 
be associated with low prevalence of AF in cirrhotics. 
The inhibitory effect (via anti-inflammatory mechanism 
or another unknown mechanism) of these drugs on 
development of AF following myocardial infarction (MI) 
and cardioversion is confirmed in several studies.[21,22] It 
should be mentioned that only 30% of our cases were on 
spironolactone or β-blockers. Statins, ACE inhibitors and 
ARBs were not used by any of our patients.
Desensitization of cardiac myocytes to catecholamine in 
cirrhotic patients is reported,[23] which may be due to down-
regulation of β–adrenergic receptors in myocardium.  [24] This 
process could be a protective mechanism against occurrence 
of tachyarrhythmias, including AF in cirrhotic patients.
Table 3: Mean left atrial size according to each age 
group
Age group 
(year)
Mean LA  
size (mm)
Age group LA size 
(mm)
Std.  
deviation
20-29 38.6 ≤49 39.5 5.465
30-39 39
40-49 40.5
50-59 40.6  ≥50 40.7 5.655
>60 40.9
Total 40
Table 1: Age and sex distribution of the study population 
and prevalence of atrial fibrillation
Age group 
(year)
Male Female Total Age ratio (%) AF (%)
20-29 137 105 242 18.5 0
30-39 120 73 193 14.8 0
40-49 256 86 342 26.3 1 (0.29)
50-59 310 88 398 30.6 0
≥60 104 23 127 9.8 1 (0.78)
Total 927 374 1302 100 2 (0.15)
Table 2: Characteristics of cirrhotic patients with atrial 
fibrillation rhythm
Age 
(y/o)
Sex LA size 
(mm)
Child 
score
HTN Diabetes Medication
71 Male 48 B - + -
45 Male 55 C - - -112  Journal of Cardiovascular Disease Research Vol. 3 / No 2
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In conclusion, the result of this study suggests that the 
prevalence of AF among cirrhotic patients is significantly 
less than the general population. Further studies seem 
beneficial to verify the possible protective mechanisms 
against development of AF in cirrhotic patients. Hopefully, 
the results of such studies may lead to new concepts 
regarding pathophysiology, prevention and treatment of AF.
Study limitation
In clinical practice, diagnosis of AF is usually based on 
physical examination, ECG and 24-h Holter monitoring. 
In our study, diagnosis of AF was based on only physical 
examination and ECG. Fortunately, our transplant center 
is a large referral center and detailed electrocardiographic 
information of these referred patients over a long period is 
available. Our hypothesis regarding AF in cirrhotic patients 
is based on these long-period ECG data.
We do believe that there are many factors that may trigger 
AF (medications, sex, age, alcohol consumption, obesity, 
hyperthyroidism, pulmonary disease, etc. Matching of 
patients with all these factors in a large number of patients, 
if not impossible, is very difficult.
Finally, we believe that our idea is just a fillip to think and 
work more in this issue. That is why we have used the 
term “Reality or Just an Illusion.” Further multicenter 
randomized studies may change this illusion into reality.
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